A Multicenter, Open-Label, Long-Term Study to Evaluate the Safety and Efficacy of OVF in Patients With Cancer and Breakthrough Pai
Phase 3
- Conditions
- Cancer pain (breakthrough pain)
- Registration Number
- JPRN-jRCT2080220447
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1)20 years old or more of age at the time of informed consent
2)Patients who have average of 1 to 4 episodes/day of breakthrough pain
3)Patients who have average of 1 to 4 episodes/day of breakthrough pain controlled by a rescue medication
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events, adverse drug reactions and efficacy
- Secondary Outcome Measures
Name Time Method